Last updated: 19 June 2019 at 2:11am EST

Julie Yu Net Worth




The estimated Net Worth of Julie Yu is at least 767 千$ dollars as of 20 March 2015. Julie Yu owns over 7,785 units of Amicus Therapeutics Inc stock worth over 651,237$ and over the last 11 years Julie sold FOLD stock worth over 116,123$.

Julie Yu FOLD stock SEC Form 4 insiders trading

Julie has made over 4 trades of the Amicus Therapeutics Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently Julie sold 8,195 units of FOLD stock worth 116,123$ on 15 June 2015.

The largest trade Julie's ever made was selling 8,195 units of Amicus Therapeutics Inc stock on 15 June 2015 worth over 116,123$. On average, Julie trades about 2,394 units every 26 days since 2014. As of 20 March 2015 Julie still owns at least 57,785 units of Amicus Therapeutics Inc stock.

You can see the complete history of Julie Yu stock trades at the bottom of the page.



What's Julie Yu's mailing address?

Julie's mailing address filed with the SEC is C/O AMICUS THERAPEUTICS, , CRANBURY, NJ, 08512.

Insiders trading at Amicus Therapeutics Inc

Over the last 17 years, insiders at Amicus Therapeutics Inc have traded over 306,740,337$ worth of Amicus Therapeutics Inc stock and bought 23,821,602 units worth 176,323,212$ . The most active insiders traders include Advisors Llcperceptive Life...Peter J BarrisPlc Gsk. On average, Amicus Therapeutics Inc executives and independent directors trade stock every 10 days with the average trade being worth of 830,419$. The most recent stock trade was executed by Bradley L Campbell on 3 September 2024, trading 7,500 units of FOLD stock currently worth 64,575$.



What does Amicus Therapeutics Inc do?

amicus therapeutics is a global, patient-centric biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. we have a unique set of platform technologies and medicines in development for patients living with the lysosomal storage disorders fabry disease and pompe disease and we are committed to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for these and other rare diseases. the needs of patients in the rare disease community are at the center of our inventive science, our commercial organization, and our clinical programs. our goal throughout all levels of the organization is to make a meaningful difference in the lives of these patients and their caregivers. several opportunities are available to join our team as we build a leading global biotechnology company focused on rare metabolic diseases. our amicus footprint spans 27 countries including our g



Complete history of Julie Yu stock trades at Amicus Therapeutics Inc

インサイダー
取引
取引
合計金額
Julie Yu
Vice President Clinical Ops
販売 116,123$
15 Jun 2015
Julie Yu
Vice President Clinical Ops
オプション行使 89,605$
20 Mar 2015
Julie Yu
Vice President Clinical Ops
購入する 22,400$
3 Oct 2014
Julie Yu
Vice President Clinical Ops
購入する 28,506$
2 Oct 2014


Amicus Therapeutics Inc executives and stock owners

Amicus Therapeutics Inc executives and other stock owners filed with the SEC include: